New Leaf Venture Partners’ Liam Ratcliffe, M.D., Ph.D., Elected to Array BioPharma’s Board of Directors

New York, NY, April 30, 2012 –New Leaf Venture Partners (NLV Partners) announced today that General Partner Liam Ratcliffe, M.D., Ph.D., has been elected as Independent Director to the Board of Directors of Array BioPharma Inc. Dr. Ratcliffe has extensive background in drug development and translational medicine, including a 12-year tenure at Pfizer.

“We are excited to announce Liam’s addition to the Array Board of Directors,” said Kyle Lefkoff, Chairman of Array BioPharma. “We believe Liam’s background in drug development will be immensely helpful as Array further advances its broadening product portfolio in oncology, as well as other major disease indications.”

Dr. Ratcliffe commented, “This is an important time for Array. As announced separately, new CEO Ron Squarer joins the Company, providing his unique outlook and perspective, and Array expects multiple data readouts from its clinical programs through the rest of 2012.”

Dr. Ratcliffe continued, “I’m honored to join the Array Board as an independent director, and I look forward to fulfilling a role in which I can reflect the broad interests of Array’s diverse shareholder base.”

Prior to joining NLV Partners, Dr. Ratcliffe served as senior vice president and development head for Pfizer Neuroscience, as well as worldwide head of Clinical Research and Development. Additional positions at Pfizer included vice president of Exploratory Development for the Mid West region, and head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories.

Dr. Ratcliffe received his M.D. and Ph.D. degrees in immunology from the University of Cape Town and his MBA degree from the University of Michigan. He completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and additional teaching hospitals in Cape Town, South Africa.

About NLV Partners
New Leaf Venture Partners is a leader in healthcare technology venture investing. Our investment professionals bring a unique blend of technical, clinical, and operational experience to our investments, working closely with our entrepreneurs and management teams to help build successful companies. We invest in both public and private biopharmaceutical companies with a focus primarily on later-stage products with near and mid-term value creating events. We also invest in commercial-stage medical device and healthcare related information technology companies.

New Leaf currently manages $1.1 billion in assets. This includes our newest fund, New Leaf Ventures II, L.P., which closed with commitments of $450 million in October 2007, New Leaf Ventures I, L.P. and the healthcare technology portfolio of the Sprout Group, one of the oldest U.S. venture capital fund groups. For more information please visit

Media: Justin Jackson, Burns McClellan on behalf of NLV Partners, +1-212-213-0006, jjackson